In a primary palliative setting, the expression of PD-L1- and Her2neu in tumor tissues might trigger targeted therapy with immune-checkpoint inhibitors or trastuzumab, respectively, however, a platinum-based chemotherapy remains the therapeutical standard2. Here, CD274 is linked to neoplasm.